BNP Paribas Financial Markets
CGEM icon

BNP Paribas Financial Markets’s Cullinan Oncology CGEM Stock Holding History

BNP Paribas Financial Markets’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$173K Sell
9,488
-20,055
-68% -$298K ﹤0.01% 4298
2026
Q1 		$420K Sell
29,543
-9,908
-25% -$127K ﹤0.01% 3680
2025
Q4 		$408K Buy
39,451
+28,780
+270% +$260K ﹤0.01% 3679
2025
Q3 		$63.3K Sell
10,671
-118,673
-92% -$869K ﹤0.01% 4496
2025
Q2 		$974K Sell
129,344
-377
-0.3% -$3.03K ﹤0.01% 2925
2025
Q1 		$982K Buy
129,721
+14,721
+13% +$141K ﹤0.01% 2800
2024
Q4 		$1.4M Buy
+115,000
New +$1.65M ﹤0.01% 2605

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

BNP Paribas Financial Markets's CGEM Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Cullinan Oncology (CGEM) stake by 68% in Q2 2026, selling an estimated $298K and leaving 9,488 shares worth $173K. The position accounts for ﹤0.01% of the portfolio, ranked #4298.

BNP Paribas Financial Markets first reported a position in CGEM in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.4M in Q4 2024. 167 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • BNP Paribas Financial Markets held 9,488 shares of Cullinan Oncology worth $173K as of Q2 2026.
  • BNP Paribas Financial Markets sold 20,055 Cullinan Oncology shares in Q2 2026, an estimated $298K.
  • Cullinan Oncology made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4298 holding.
  • BNP Paribas Financial Markets first reported a position in Cullinan Oncology in Q4 2024 and has held it in 7 quarters since.
  • BNP Paribas Financial Markets's Cullinan Oncology position peaked at $1.4M in Q4 2024.
  • 167 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.